Novel Immunotherapy Agent Tebentafusp for Treatment of Metastatic Uveal Melanoma

Source: Onc Live, July 2022

Dr Omid Hamid explains the mechanism of action of recently approved tebentafusp for mUM, and why HLA testing is necessary for patients being considered for the treatment.

READ THE ORIGINAL FULL ARTICLE

Menu